February 05, 2018
A former Aveo Pharmaceuticals Inc. executive continued to argue in Massachusetts federal court Monday that he should not have to pay a fine or be barred from leadership positions over the Securities and Exchange Commission's allegations that he deceived investors about Aveo's flagship kidney cancer drug, saying he had learned his lesson.
January 17, 2018
Aveo Pharmaceuticals Inc.'s former chief medical officer told a Massachusetts federal court Tuesday that he shouldn't have to pay a fine or be barred from leadership positions because the U.S. Securities & Exchange Commission exaggerated his alleged role in deceiving investors about Aveo's kidney cancer drug, Tivo.
November 09, 2017
A Massachusetts magistrate judge will decide whether Aveo Pharmaceuticals Inc.'s former chief medical officer should pay a civil penalty under a deal that would resolve the U.S. Securities and Exchange Commission's allegations that he hid from investors the Food and Drug Administration's concerns about its flagship kidney cancer drug.
March 29, 2016
Massachusetts-based biotechnology company Aveo Pharmaceuticals Inc. will pay $4 million to settle the U.S. Securities and Exchange Commission's allegations it hid from investors the Food and Drug Administration's concerns over its flagship kidney cancer drug, the SEC said Tuesday.